1921
Volume 73, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Medical records of 77 patients with Q fever pneumonia that was serologically confirmed by enzyme-linked immunosorbent assay were studied to compare the clinical efficacy of doxycycline, clarithromycin, and moxifloxacin. The mean times to defervescence were 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin. There were no interruptions of the regimens in any groups because of side effects, and outcome was favorable in all patients with no complications or relapses during follow-up. This efficacy of clarithromycin and moxifloxacin, together with their safety profiles, suggest that these alternative agents in the treatment of Q fever pneumonia could also be used as the first-line therapy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2005.73.947
2005-11-01
2017-11-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/73/5/0730947.html?itemId=/content/journals/10.4269/ajtmh.2005.73.947&mimeType=html&fmt=ahah

References

  1. Spelman DW, 1982. Q fever: a study of 111 consecutive cases. Med J Aust 1 : 547–553.
  2. Dumler JS, 2002. Q fever. Curr Treat Options Infect Dis 4 : 437–445.
  3. Marrie TJ, 2004. Q fever pneumonia. Curr Opin Infect Dis 17 : 137–142.
  4. File TM Jr, Tan JS, 2003. International guidelines for the treatment of community-acquired pneumonia in adult: the role of macrolides. Drugs 63 : 181–205.
  5. Hoeffken D, Talan D, Larsen LS, Peloquin S, Choudri SH, Haverstock D, Jackson P, Church D, 2004. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 23 : 772–775.
  6. Maurin M, Benoliel AM, Bongrand P, Raoult D, 1992. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 166 : 1097–1102.
  7. Maurin M, Raoult D, 1993. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 37 : 2633–2637.
  8. Gikas A, Spyridaki I, Psaroulaki A, Kofteridis DP, Tselentis Y, 1998. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob Agents Chemother 42 : 2747–2748.
  9. Rolain J-M, Maurin M, Raoult D, 2001. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother 45 : 301–302.
  10. Lever MS, Bewley KR, Dowsett B, Lloyd G, 2004. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Int J Antimicrob Agents 24 : 194–196.
  11. Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y, 2001. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 45 : 3644–3646.
  12. Dzelalija B, Morovic M, Stankovic S, Vukic L, Dobec M, Dujella J, 1990. Clinical spectrum of rickettsioses in the Zadar area. Lijec Vjesn 112 : 102–105.
  13. Gikas A, Spyridaki I, Scoulica E, Psaroulaki A, Tselentis Y, 2001. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. Antimicrob Agents Chemother 45 : 3276–3278.
  14. Maurin M, Raoult D, 1999. Q fever. Clin Microbiol Rev 12 : 518–553.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2005.73.947
Loading
/content/journals/10.4269/ajtmh.2005.73.947
Loading

Data & Media loading...

  • Received : 11 Feb 2005
  • Accepted : 15 Apr 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error